<p>近期製藥行業中較受歡迎的股票之一在週二遭到了投資者的冷遇。<strong>禮來</strong>(LLY -5.50%) 今天的交易收盤時價值下跌近 6%，這明顯遜色於基準 <strong>標準普爾 500</strong> 指數的 0.3% 的跌幅。不過，這一下降並不完全是禮來的錯。</p>
<h2>減重，降低指引</h2>
<p>禮來最近的受歡迎程度在很大程度上歸功於其進入了利潤豐厚的減肥藥市場。在 2023 年底，其 Zepbound——本質上與其糖尿病藥物 Mounjaro 相同的治療——獲得了治療肥胖的批准，公司因此迅速發展。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjcxMjMvaGVhbHRoY2FyZS1wcm9mZXNzaW9uYWwtaW5zcGVjdGluZy1jaGFydHMuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjcxMjMvaGVhbHRoY2FyZS1wcm9mZXNzaW9uYWwtaW5zcGVjdGluZy1jaGFydHMuanBnJnc9NzAw"/></p>
<p>圖片來源：Getty Images。</p>
<p>然而在週二，該領域的標杆 <strong>諾和諾德</strong> 卻遭遇了大跌。今天早上，該公司下調了全年銷售和營業利潤的指引。</p>
<p>前者的增長預測被下調至 2024 年 8% 至 14%（之前的指引範圍為 13% 至 21%）。營業利潤的預期也相同，現在預計增長範圍為 10% 至 16%。如果不是因為管理層之前的預測為 16% 至 24%，這將是令人鼓舞的。</p>
<p>諾和諾德以開發和銷售 Wegovy 而聞名，這是美國食品藥品監督管理局專門批准用於減肥的首個 GLP-1 藥物。該公司憑藉這一藥物飛速崛起並贏得了讚譽，而這仍然是其關鍵產品。投資者可能擔心禮來的 Zepbound 也會表現不如預期。</p>
<h2>不是緊急情況</h2>
<p>我認為沒有人應該因為這個（或諾和諾德）而對禮來按下恐慌按鈕。對肥胖藥物的需求依然強勁且幾乎沒有限制，因此 Zepbound 和 Wegovy——至少目前仍受益於缺乏競爭對手——應該繼續成為增長驅動力。</p>
<p>此外，就禮來而言，這家龐大的製藥公司擁有廣泛的產品組合和非常廣泛的開發管道，因此它並不依賴於一種藥物——無論該藥物目前有多受歡迎。</p>

禮來

<p>禮來的股票下跌近 6%，表現遜色於標準普爾 500 指數的 0.3% 下跌，主要是由於對其減肥藥 Zepbound 表現的擔憂，此前諾和諾德下調了銷售和利潤預期。儘管出現下滑，分析師認為肥胖藥物的需求依然強勁，禮來的多元化產品組合降低了與任何單一產品相關的風險</p>

<p>One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. <strong>Eli Lilly</strong>(LLY -5.50%) closed today's trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether <strong>S&amp;P 500</strong> index. That decline wasn't necessarily Eli Lilly's fault, though.</p>
<div class="lb-trans"><p>近期製藥行業中較受歡迎的股票之一在週二遭到了投資者的冷遇。<strong>禮來</strong>(LLY -5.50%) 今天的交易收盤時價值下跌近 6%，這明顯遜色於基準 <strong>標準普爾 500</strong> 指數的 0.3% 的跌幅。不過，這一下降並不完全是禮來的錯。</p>
</div><h2>Reducing weight, reducing guidance</h2>
<div class="lb-trans"><h2>減重，降低指引</h2>
</div><p>Eli Lilly's recent popularity is due in no small measure to its plunge into the highly lucrative weight-loss drug market. In late 2023, its Zepbound -- essentially the same treatment as its diabetes drug Mounjaro -- was approved to treat obesity, and the company was off to the races.</p>
<div class="lb-trans"><p>禮來最近的受歡迎程度在很大程度上歸功於其進入了利潤豐厚的減肥藥市場。在 2023 年底，其 Zepbound——本質上與其糖尿病藥物 Mounjaro 相同的治療——獲得了治療肥胖的批准，公司因此迅速發展。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MjcxMjMvaGVhbHRoY2FyZS1wcm9mZXNzaW9uYWwtaW5zcGVjdGluZy1jaGFydHMuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F827123%2Fhealthcare-professional-inspecting-charts.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><p>On Tuesday, though, the standard-bearer for the segment took quite a tumble. That was <strong>Novo Nordisk</strong>, which this morning lowered its guidance for both full-year sales and operating profit.</p>
<div class="lb-trans"><p>然而在週二，該領域的標杆 <strong>諾和諾德</strong> 卻遭遇了大跌。今天早上，該公司下調了全年銷售和營業利潤的指引。</p>
</div><p>The growth forecast for the former was reduced to 8% to 14% over the 2024 tally (previous guidance range: 13% to 21%). Ditto for operating profit, which is now expected to rise in a range of 10% to 16%. That would be encouraging, if it weren't for the fact that management's preceding prediction was 16% to 24%.</p>
<div class="lb-trans"><p>前者的增長預測被下調至 2024 年 8% 至 14%（之前的指引範圍為 13% 至 21%）。營業利潤的預期也相同，現在預計增長範圍為 10% 至 16%。如果不是因為管理層之前的預測為 16% 至 24%，這將是令人鼓舞的。</p>
</div><p>Novo Nordisk is known for developing and selling Wegovy, the first GLP-1 drug approved by the U.S. Food and Drug Administration specifically for weight loss. The company has flown to renown and admiration on the wings of that drug, which remains a key product. Investors probably fear that Eli Lilly's Zepbound will also perform worse than expected.</p>
<div class="lb-trans"><p>諾和諾德以開發和銷售 Wegovy 而聞名，這是美國食品藥品監督管理局專門批准用於減肥的首個 GLP-1 藥物。該公司憑藉這一藥物飛速崛起並贏得了讚譽，而這仍然是其關鍵產品。投資者可能擔心禮來的 Zepbound 也會表現不如預期。</p>
</div><h2>Not an emergency</h2>
<div class="lb-trans"><h2>不是緊急情況</h2>
</div><p>I don't think anyone should push the panic button on Eli Lilly due to this (or Novo Nordisk, while I'm at it). Demand for obesity drugs remains strong and nearly unlimited, so both Zepbound and Wegovy -- which still benefit from a lack of competitors, at least for now -- should continue to be growth drivers.</p>
<div class="lb-trans"><p>我認為沒有人應該因為這個（或諾和諾德）而對禮來按下恐慌按鈕。對肥胖藥物的需求依然強勁且幾乎沒有限制，因此 Zepbound 和 Wegovy——至少目前仍受益於缺乏競爭對手——應該繼續成為增長驅動力。</p>
</div><p>Also, in the case of Eli Lilly, the sprawling pharmaceutical company has a vast portfolio and a very wide development pipeline, so it's hardly dependent on one drug -- no matter how currently popular that drug might be.</p>
<div class="lb-trans"><p>此外，就禮來而言，這家龐大的製藥公司擁有廣泛的產品組合和非常廣泛的開發管道，因此它並不依賴於一種藥物——無論該藥物目前有多受歡迎。</p>
</div>

為什麼禮來的股票今天表現不佳